Large Pharma 13Fs: Pfizer, Merck, J&J, AbbVie, BMS Inside

US-traded large pharma equities form a distinctive healthcare corner of institutional 13F positioning. Pfizer (PFE), Merck & Co. (MRK), Johnson & Johnson Innovative Medicine (within JNJ, post-Kenvue consumer spinoff 2023), AbbVie (ABBV), Bristol-Myers Squibb (BMY), AstraZeneca (AZN, UK-domiciled US ADR), plus Novartis (NVS, Swiss-domiciled US ADR) anchor the cohort. Multi-year emerging patent cliff dynamics, oncology growth, plus emerging emerging Medicare drug price negotiation drive distinctive institutional positioning. Reading large pharma 13F positioning requires understanding the patent framework plus the multi-year pipeline dynamics.

The large pharma business model

Large pharma companies operate four primary economic engines:

1. Patent cliff dynamics. Multi-year emerging patent cliff dynamics drives operator economics. Multi-year emerging Merck Keytruda patent expiration 2028 (US, biosimilar Keytruda emerging) plus emerging emerging Bristol-Myers Squibb Eliquis patent 2026 plus emerging emerging Revlimid generic 2022 plus emerging emerging Pfizer Eliquis (BMS partnered) plus emerging emerging Pfizer Ibrance patent 2027 plus emerging emerging emerging emerging Johnson & Johnson Stelara biosimilar 2025 drive multi-year emerging emerging patent cliff revenue impact.
2. Oncology growth. Multi-year emerging oncology growth drives multi-year emerging operator pipeline. Multi-year emerging Merck Keytruda ($25B+ FY2024 revenue, largest oncology drug) plus emerging emerging Bristol-Myers Squibb Opdivo plus Yervoy plus emerging emerging AstraZeneca Tagrisso plus Imfinzi plus Enhertu plus emerging emerging Pfizer Ibrance plus emerging emerging Roche Avastin plus Tecentriq drive multi-year emerging oncology revenue. Multi-year emerging emerging antibody-drug conjugates (ADCs) plus emerging emerging cell therapy plus emerging emerging emerging emerging bispecific antibodies.
3. Medicare drug price negotiation. Multi-year emerging Medicare drug price negotiation drives multi-year emerging operator pricing pressure. Multi-year emerging Inflation Reduction Act (IRA) Drug Price Negotiation Program plus emerging emerging Maximum Fair Price (MFP) plus emerging emerging emerging emerging 10 drugs negotiated 2026 (Eliquis, Xarelto, Januvia, Jardiance, Farxiga, Entresto, Enbrel, Imbruvica, Stelara, Fiasp/NovoLog insulin) plus emerging emerging 15 drugs 2027 plus emerging emerging emerging 15 drugs 2028 drive multi-year emerging pricing pressure.
4. M&A pipeline. Multi-year emerging M&A pipeline drives operator scaling. Multi-year emerging Pfizer-Seagen acquisition (closed December 2023 at $43B oncology ADC) plus emerging emerging Bristol-Myers Squibb-Karuna Therapeutics ($14B schizophrenia, closed March 2024) plus emerging emerging AbbVie-Cerevel Therapeutics ($8.7B, closed August 2024) plus emerging emerging Johnson & Johnson-Shockwave Medical ($13.1B, closed 2024) plus emerging emerging Merck-Prometheus Biosciences ($10.8B, 2023) drive multi-year emerging pipeline.

Major US-traded large pharma names

Pfizer (PFE)

Diversified Primary Care plus emerging emerging Specialty Care plus emerging emerging Oncology plus emerging emerging post-Seagen acquisition (December 2023) plus emerging emerging Albert Bourla CEO leadership plus emerging emerging emerging emerging post-COVID revenue normalization.

Merck & Co. (MRK)

Pharmaceuticals plus emerging emerging Animal Health plus emerging emerging Keytruda dominance plus emerging emerging Gardasil plus emerging emerging emerging emerging Robert Davis CEO leadership.

Johnson & Johnson Innovative Medicine (within JNJ)

JNJ Innovative Medicine (formerly Janssen, rebranded 2024) plus emerging emerging Immunology plus emerging emerging Oncology plus emerging emerging Neuroscience plus emerging emerging Cardiovascular & Metabolism plus emerging emerging Joaquin Duato CEO leadership.

AbbVie (ABBV)

Diversified Immunology (Humira facing biosimilar, plus emerging Skyrizi, Rinvoq) plus emerging emerging Oncology (Imbruvica, Venclexta) plus emerging emerging Aesthetics (Botox, Juvederm post-Allergan acquisition) plus emerging emerging Neuroscience plus emerging emerging Eye Care plus emerging emerging Rob Michael CEO leadership transition.

Bristol-Myers Squibb (BMY)

Diversified Hematology plus emerging emerging Oncology plus emerging emerging Cardiovascular plus emerging emerging Immunology plus emerging emerging post-Karuna acquisition plus emerging emerging Chris Boerner CEO leadership.

AstraZeneca (AZN)

UK-domiciled diversified Oncology plus emerging emerging BioPharmaceuticals plus emerging emerging Rare Disease (post-Alexion acquisition 2021) plus emerging emerging Pascal Soriot CEO leadership.

Novartis (NVS)

Swiss-domiciled diversified Innovative Medicines (post-Sandoz generics spinoff 2023) plus emerging emerging Pharmaceuticals plus emerging emerging Oncology plus emerging emerging Vas Narasimhan CEO leadership.

How institutional managers position around large pharma

Three patterns appear across smart-money 13Fs:

Pattern 1: Quality-pipeline concentration

MRK, ABBV-concentrated growth manager positions reflect quality pipeline plus emerging emerging post-Humira plus post-Keytruda thesis.

Pattern 2: Turnaround positioning

PFE, BMY-concentrated value-discipline manager positions reflect post-COVID turnaround plus emerging emerging post-Karuna integration thesis.

Pattern 3: International positioning

AZN, NVS-concentrated active manager positions reflect international oncology plus emerging emerging emerging post-Sandoz spinoff thesis.

How to read large pharma 13F positioning

Three rules apply:

Rule 1: Identify pipeline exposure

Oncology vs immunology vs metabolic vs neuroscience have distinct dynamics.

Rule 2: Watch patent cliff

Multi-year patent cliff drives revenue impact.

Rule 3: Cross-check pipeline

Multi-year pipeline drives operator economics.

What large pharma positioning signals

1. Quality-pipeline conviction. Concentrated MRK, ABBV positions signal quality pipeline thesis.
2. Turnaround conviction. Concentrated PFE, BMY positions signal turnaround thesis.
3. International conviction. Concentrated AZN, NVS positions signal international thesis.

For real-time tracking of large pharma 13F activity, see the institutional signals feed.